Cullinan Oncology (NASDAQ:CGEM – Get Free Report) had its price objective decreased by stock analysts at HC Wainwright from $29.00 to $28.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 11.82% from the company’s current price. […]
Stifel Nicolaus initiated coverage on shares of Cullinan Oncology (NASDAQ:CGEM – Free Report) in a report released on Wednesday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $40.00 price objective on the stock. Several other brokerages have also weighed in on CGEM. HC Wainwright decreased their price objective on Cullinan Oncology […]
Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Free Report) shares reached a new 52-week high during mid-day trading on Friday . The stock traded as high as $21.89 and last traded at $21.36, with a volume of 288839 shares changing hands. The stock had previously closed at $19.25. Analyst Ratings Changes A number of analysts recently […]
Explore the use of Amgen's Blincyto in treating severe systemic sclerosis, shedding light on Cullinan Therapeutics' CLN-978 potential for autoimmune diseases, particularly systemic lupus erythematosus.
A recent academic case study, published on April 22, examined using Amgen Inc’s AMGN Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with…